Press "Enter" to skip to content

Hansoh Pharma’s AMEILE (almonertinib) Receives Marketing Authorization in China for Second-line Treatment for Patients With EGFR T790m-mutation Non-small Cell Lung Cancer – BioSpace

admin 0

Hansoh Pharma’s AMEILE (almonertinib) Receives Marketing Authorization in China for Second-line Treatment for Patients With EGFR T790m-mutation Non-small Cell Lung Cancer  BioSpace
“lung cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *